In a statement on Saturday, the company said that the drug, already approved for conditions like psoriasis and arthritis, demonstrated rapid and sustained relief in trial participants suffering from hidradenitis suppurativa.
The company said the painful inflammatory skin disease, for which few treatments are available, affects about 1% of the population but is difficult to diagnose.Novartis will become more reliant on drug development as it plans to spin off its generics unit Sandoz, which makes low-cost copies of treatments that have lost patent protection.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: